 SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 GLOBE NEWSWIRE -- CytomX Therapeutics, Inc. Nasdaq: CTMX, a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody technology platform, today announced that on October 15, 2021, the Company granted six new employees options to purchase a total of 177,000 shares of the Companys common stock at an exercise price per share equal to 5.14, which was the closing trading price on October 15, 2021, the date of the grant. 